Clinical trials: Upper Limb
Healthy
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
The purpose of this study is to determine the effect of quinidine on the levels of orforglipron in the blood stream and how long it takes the body to eliminate it, when administered orally in healthy participants.
- Trial name
- NCT06704763
- Testing
- Orforglipron, Midazolam, Quinidine
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Vaccines, Pneumococcal Conjugate Vaccine
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
This is a follow-up study to the core study NCT00269672 (6115A1-500). This study will further evaluate the safety, tolerability, and immunogenicity of 13-valent pneumococcal conjugate vaccine (13vPnC) when administered to…
- Trial name
- NCT00500357
- Testing
- 13-valent Pneumococcal Conjugate Vaccine
- Where
- 16 sites in South Africa
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Rheumatoid Arthritis
MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis
The purpose of the study is to compare the efficacy, safety and immunogenicity of MSB11456 and EU approved RoActemra® in participants with moderately to severely active rheumatoid arthritis.
- Trial name
- NCT04512001
- Testing
- MSB11456, EU-approved RoActemra
- Where
- 85 sites in Bulgaria, Czechia and 7 more
- Volunteers
- 604 people
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Photodamaged Skin, Wrinkles
Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles
The purpose of this study is to assess the comparative efficacy of retinol 1.0% and tretinoin 0.02% in minimizing wrinkles, discoloration, roughness, and other signs of moderate to severe photodamage.
- Trial name
- NCT01283464
- Testing
- Retinol, Tretinoin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Johns Hopkins University
May-Thurner Syndrome, Peripheral Vascular Disease
BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease
The BARD® Venovo™ Venous Stent Study is a non-randomized clinical study intended to collect confirmatory evidence of the safety and effectiveness of the Venous Stent for the treatment of iliofemoral occlusive disease.
- Conditions
- May-Thurner Syndrome, Peripheral Vascular Disease, Venous Disease, Iliofemoral Occlusive Disease
- Trial name
- VERNACULAR (NCT02655887)
- Testing
- VENOVO™ Venous Stent
- Where
- 21 sites in United States, Australia and 5 more
- Volunteers
- 170 people
- Sponsor
- C. R. Bard
Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01118351
- Testing
- sunitinib malate, immunohistochemistry staining method, TdT-mediated dUTP nick end labeling assay
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Case Comprehensive Cancer Center
Amyloidosis
A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
This study evaluates the safety and efficacy of carfilzomib used in combination with thalidomide and dexamethasone in patients with relapsed AL amyloidosis.
- Trial name
- CATALYST (NCT02545907)
- Testing
- Carfilzomib, Thalidomide, Dexamethasone
- Where
- 14 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- University College, London
Chronic Migraine
Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine
This study is intended to evaluate the efficacy and safety of Nerivio, an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine, for the acute treatment of migraine in people with…
- Trial name
- NCT04161807
- Testing
- Nerivio
- Where
- 2 sites in United States, Israel
- Volunteers
- 42 people
- Sponsor
- Theranica
Hypertension, Pulmonary
Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)
The MOTION study was a prospective, Phase IV study for patients with Pulmonary Arterial Hypertension (PAH). The study was designed to further explore patient-reported outcomes in PAH subjects who were not on active treatment and…
- Trial name
- NCT02191137
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 59 sites in United States, Puerto Rico
- Volunteers
- 75 people
- Sponsor
- Bayer
Coronary Artery Disease, Coronary Disease
Sapphire II PRO US Clinical Study
A prospective, open label, multi-center, single arm, observational study designed to evaluate the acute safety and device procedural success of the Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters in subjects with…
- Conditions
- Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases
- Trial name
- NCT03052530
- Testing
- Sapphire II PRO
- Where
- 4 sites in United States
- Volunteers
- 61 people
- Sponsor
- OrbusNeich
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
The initial intent of the study was to be a multi-center single-arm open-label Simon's two-stage Phase II clinical trial of first-line mFOLFOX6 + trastuzumab + avelumab in metastatic HER2-amplified gastric and esophageal…
- Conditions
- Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Metastasis, HER-2 Gene Amplification
- Trial name
- NCT03783936
- Testing
- Oxaliplatin, Leucovorin, 5 fluorouracil
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ashwin Somasundaram
Healthy
To Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17
This study was phase 1, randomized, open-label, two-arm, parallel group, single-dose study, which was designed to compare the pharmacokinetics (PK) and safety of CT-P17 SC administration via AI and PFS in healthy subjects.
- Trial name
- NCT04295356
- Testing
- CT-P17
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Celltrion
Relapsing Forms of Multiple Sclerosis
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
The purpose of this study was to collect long-term safety and tolerability, long-term efficacy, and health outcome data in all patients currently ongoing in the fingolimod multiple sclerosis clinical development program.
- Trial name
- NCT01201356
- Testing
- Fingolimod
- Where
- 458 sites in United States, Argentina and 36 more
- Volunteers
- 4,125 people
- Sponsor
- Novartis Pharmaceuticals
Contraception
Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy
The purpose of this study is to assess the contraceptive efficacy of relugolix combination therapy.
- Trial name
- SERENE (NCT04756037)
- Testing
- Relugolix Combination Therapy
- Where
- 112 sites in United States, Puerto Rico
- Volunteers
- 1,164 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Finger Stiffness, Distal Radius Fracture
Does Vitamin C Reduce Finger Stiffness After Distal Radius Fractures?
The reported prevalence of disproportionate pain and disability among patients recovering from a fracture of the distal radius varies widely.
- Trial name
- NCT02216812
- Testing
- 500 mg vitamin c, 1 pill per day for 6 weeks
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- Massachusetts General Hospital
Chronic Hand Eczema
Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema
The purpose of this research trial was to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects chronic hand eczema.
- Trial name
- NCT03683719
- Testing
- Delgocitinib cream, Delgocitinib cream vehicle
- Where
- 28 sites in United States, Denmark and 1 more
- Volunteers
- 258 people
- Sponsor
- LEO Pharma
Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
Efficacy and Safety of RTH258 Versus Aflibercept - Study 2
The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection (6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal…
- Trial name
- HARRIER (NCT02434328)
- Testing
- Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
- Volunteers
- 1,048 people
- Sponsor
- Alcon Research
Acute Lymphoblastic Leukemia
SPARK-ALL: Calaspargase Pegol in Adults With ALL
The purpose of this phase 2/3 study is to confirm the recommended doses and to evaluate the safety and pharmacodynamics of Calaspargase pegol for the treatment of adult patients with Philadelphia-negative Acute Lymphoblastic…
- Trial name
- NCT04817761
- Testing
- Calaspargase pegol (S95015)
- Where
- 21 sites in United States
- Volunteers
- 42 people
- Sponsor
- Institut de Recherches Internationales Servier
Growth Hormone Deficiency, Endocrine System Diseases
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
A 38-week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control.
- Conditions
- Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
- Trial name
- foresiGHt (NCT04615273)
- Testing
- Lonapegsomatropin, Somatropin
- Where
- 113 sites in United States, Armenia and 22 more
- Volunteers
- 264 people
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
Epilepsy
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
To study how the body absorbs, distributes, metabolises and eliminates Keppra XR in both children (12 to 16 years old) and adults (18 to 55 years old) with epilepsy.
- Trial name
- NCT00961441
- Testing
- Keppra XR
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- UCB BIOSCIENCES, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.